Literature DB >> 28763306

Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials.

Khagendra Dahal1, Sharan P Sharma, Jaspreet Kaur, Billie J Anderson, Gurpinder Singh.   

Abstract

BACKGROUND: Long-term aspirin use in cardiovascular disease prevention may result in gastrointestinal bleeding. Although proton pump inhibitors (PPI) have been shown to reduce the risks of peptic ulcers and dyspeptic symptoms in long-term aspirin users in the randomized controlled trials, there are safety concerns about the long-term use of PPI. STUDY QUESTION: What is the safety and efficacy of PPI in patients using aspirin in long term for prevention of cardiovascular diseases and stroke?
METHODS: We searched MEDLINE, EMBASE, CENTRAL, CINAHL, ProQuest, and relevant references from inception through February 2015, and used random-effects model for meta-analysis.
RESULTS: A total of 10 publications from 9 studies (n = 6382) were included in the meta-analysis. Compared with control, PPI reduced the risks of peptic ulcers [risk ratio (RR): 0.19; 95% confidence interval: 0.13-0.26; P < 0.00001], gastric ulcers [0.24 (0.16-0.35); P < 0.00001], duodenal ulcers [0.12 (0.05-0.29); P < 0.00001], bleeding ulcers [0.22 (0.10-0.51); P = 0.0004], and erosive esophagitis [0.14 (0.07-0.28); P < 0.00001]. PPI increased the resolution of epigastric pain [1.13 (1.03-1.25); P = 0.01], heartburn [1.24 (1.18-1.31); P < 0.00001], and regurgitation [1.26 (1.13-1.40); P < 0.0001], but did not increase the risks of all-cause mortality [1.72 (0.61-4.87); P = 0.31], cardiovascular mortality [1.80 (0.59-5.44); P = 0.30], nonfatal myocardial infarction/ischemia [0.56 (0.22-1.41); P = 0.22], ischemic stroke/transient ischemic attack [1.09 (0.34-3.53); P = 0.89] and other adverse events.
CONCLUSIONS: The PPI seems to be effective in preventing peptic ulcers and erosive esophagitis and in resolution of dyspeptic symptoms without increasing adverse events, cardiac risks or mortality in long-term aspirin users.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28763306     DOI: 10.1097/MJT.0000000000000637

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  5 in total

Review 1.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Authors:  Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

Review 2.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

Review 3.  The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis.

Authors:  Dalel Jeridi; Anna Pellat; Claire Ginestet; Antoine Assaf; Rachel Hallit; Felix Corre; Romain Coriat
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

Review 4.  Clinical use of low-dose aspirin for elders and sensitive subjects.

Authors:  Yan Zhang; Xiang-Ming Fang; Guo-Xun Chen
Journal:  World J Clin Cases       Date:  2019-10-26       Impact factor: 1.337

5.  Antiulcerogenic Activity of Li-Zhong Decoction on Duodenal Ulcers Induced by Indomethacin in Rats: Involvement of TLR-2/MyD88 Signaling Pathway.

Authors:  Houpan Song; Meiyan Zeng; Xiaojuan Chen; Xinyi Chen; Jun Peng; Ye Lin; Rong Yu; Xiong Cai; Qinghua Peng
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-21       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.